利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

25 条记录 (耗时 0.053 秒)

    Amphiregulin antibodies and their use to treat cancer and psoriasis
    2.
    发明授权
    Amphiregulin antibodies and their use to treat cancer and psoriasis 有权
    双调蛋白抗体及其用于治疗癌症和牛皮癣的用途

    公开(公告)号：US07223393B2

    公开(公告)日：2007-05-29

    申请号：US10774076

    申请日：2004-02-06

    申请人： Nicholas F. Landolfi ,  Naoya Tsurushita ,  Paul R. Hinton ,  Shankar Kumar

    发明人： Nicholas F. Landolfi ,  Naoya Tsurushita ,  Paul R. Hinton ,  Shankar Kumar

    IPC分类号： A61K39/395

    CPC分类号： G01N33/574 ,  A61K47/6855 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/73 ,  G01N2333/485

    摘要： The present invention is directed to anti-AR antibodies, preferably humanized monoclonal antibodies having the amino acid sequences disclosed herein. The present invention includes a pharmaceutical composition comprising such antibodies. The present invention includes a method of inhibiting cancer cell growth comprising administering such antibodies into a subject. The present invention also provides a method of treating cancer or psoriasis in a subject in need of such a treatment by administering such antibodies to said subject in a pharmaceutically effective amount.

    摘要翻译： 本发明涉及抗AR抗体，优选具有本文公开的氨基酸序列的人源化单克隆抗体。 本发明包括含有这种抗体的药物组合物。 本发明包括抑制癌细胞生长的方法，其包括向受试者施用此类抗体。 本发明还提供了通过以药学上有效量向所述受试者施用这种抗体来治疗需要这种治疗的受试者中的癌症或牛皮癣的方法。

    Alteration of Fc-fusion protein serum half-lives by mutagenesis
    3.
    发明授权
    Alteration of Fc-fusion protein serum half-lives by mutagenesis 有权
    通过诱变改变Fc融合蛋白血清半衰期

    公开(公告)号：US07217798B2

    公开(公告)日：2007-05-15

    申请号：US10966673

    申请日：2004-10-15

    申请人： Paul R. Hinton ,  Naoya Tsurushita

    发明人： Paul R. Hinton ,  Naoya Tsurushita

    IPC分类号： C12P21/08 ,  C12P21/06 ,  C12P21/04 ,  C07K16/00 ,  C12N15/00

    CPC分类号： C07K14/7151 ,  C07K14/5437 ,  C07K14/70528 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/30

    摘要： The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.

    摘要翻译： 本发明提供了修饰的Fc融合蛋白，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一种不同于此的氨基酸取代 存在于未修饰的Fc融合蛋白中，从而与未修饰的Fc融合蛋白相比，改变了FcRn的结合亲和力和/或血清半衰期。

    IL-12/p40 binding proteins
    4.
    发明授权
    IL-12/p40 binding proteins 失效
    IL-12 / p40结合蛋白

    公开(公告)号：US08629257B2

    公开(公告)日：2014-01-14

    申请号：US12763048

    申请日：2010-04-19

    申请人： Susan E. Lacy ,  Emma Fung ,  Jonathan P. Belk ,  Richard W. Dixon ,  Michael Roguska ,  Paul R. Hinton ,  Shankar Kumar

    发明人： Susan E. Lacy ,  Emma Fung ,  Jonathan P. Belk ,  Richard W. Dixon ,  Michael Roguska ,  Paul R. Hinton ,  Shankar Kumar

    IPC分类号： C07H21/04

    CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

    摘要： The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

    摘要翻译： 本发明包括IL-12p40结合蛋白，特别是结合人白细胞介素-12（hIL-12）和/或人IL-23（hIL-23）的抗体。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-12和/或hIL-23具有高亲和力，并在体外和体内中和h IL-12和/或hIL-23活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-12和/或hIL-23和用于抑制hIL-12和/或hIL-23活性，例如在患有hIL -12和/或hIL-23活性是有害的。

    Alteration of Fc-fusion protein serum half-lives by mutagenesis
    5.
    发明授权
    Alteration of Fc-fusion protein serum half-lives by mutagenesis 有权
    通过诱变改变Fc融合蛋白血清半衰期

    公开(公告)号：US07732570B2

    公开(公告)日：2010-06-08

    申请号：US11803694

    申请日：2007-05-14

    申请人： Paul R. Hinton ,  Naoya Tsurushita

    发明人： Paul R. Hinton ,  Naoya Tsurushita

    IPC分类号： C07K1/00 ,  C07K16/00 ,  C12P21/08 ,  A61K39/00

    CPC分类号： C07K14/7151 ,  C07K14/5437 ,  C07K14/70528 ,  C07K16/00 ,  C07K2317/52 ,  C07K2319/30

    摘要： The present invention provides for a modified Fc-fusion protein in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified Fc-fusion protein, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified Fc-fusion protein.

    摘要翻译： 本发明提供了修饰的Fc融合蛋白，其中来自选自氨基酸残基250,314和428的重链恒定区的至少一个氨基酸被另一种不同于此的氨基酸取代 存在于未修饰的Fc融合蛋白中，从而与未修饰的Fc融合蛋白相比，改变了FcRn的结合亲和力和/或血清半衰期。

    IL-12/P40 BINDING PROTEINS
    6.
    发明申请
    IL-12/P40 BINDING PROTEINS 有权
    IL-12 / P40结合蛋白

    公开(公告)号：US20100047245A1

    公开(公告)日：2010-02-25

    申请号：US11478096

    申请日：2006-06-29

    申请人： Susan E. Lacy ,  Emma Fung ,  Jonathan P. Belk ,  Richard W. Dixon ,  Michael Roguska ,  Paul R. Hinton ,  Shankar Kumar

    发明人： Susan E. Lacy ,  Emma Fung ,  Jonathan P. Belk ,  Richard W. Dixon ,  Michael Roguska ,  Paul R. Hinton ,  Shankar Kumar

    IPC分类号： A61K39/395 ,  C07K16/18 ,  C07H21/04 ,  C12N15/74 ,  C12N1/21 ,  C12N5/10 ,  C12N1/19 ,  C12N5/071 ,  A61P37/06

    CPC分类号： C07K16/244 ,  A61K39/3955 ,  A61K45/06 ,  C07K2317/24 ,  C07K2317/567 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/6869

    摘要： The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

    摘要翻译： 本发明包括IL-12p40结合蛋白，特别是结合人白细胞介素-12（hIL-12）和/或人IL-23（hIL-23）的抗体。 具体地，本发明涉及作为嵌合，CDR移植和人源化抗体的抗体。 优选的抗体对hIL-12和/或hIL-23具有高亲和力，并在体外和体内中和h IL-12和/或hIL-23活性。 本发明的抗体可以是全长抗体或其抗原结合部分。 还提供了制备方法和使用本发明抗体的方法。 本发明的抗体或抗体部分可用于检测hIL-12和/或hIL-23和用于抑制hIL-12和/或hIL-23活性，例如在患有hIL -12和/或hIL-23活性是有害的。

    Anti-CCR5 antibody
    7.
    发明授权
    Anti-CCR5 antibody 有权
    抗CCR5抗体

    公开(公告)号：US07666419B2

    公开(公告)日：2010-02-23

    申请号：US11581945

    申请日：2006-10-16

    申请人： William C. Olson ,  Paul J. Maddon ,  Naoya Tsurushita ,  Paul R. Hinton ,  Maximillano Vasquez

    发明人： William C. Olson ,  Paul J. Maddon ,  Naoya Tsurushita ,  Paul R. Hinton ,  Maximillano Vasquez

    IPC分类号： A61K39/395 ,  C12N15/13 ,  C07K16/28

    CPC分类号： C07K16/2866 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76

    摘要： The invention is directed an anti-CCR5 antibody which comprises (i) two light chains, each light chain comprising the expression product of a plasmid designated pVK:HuPRO14O-VK (ATCC Deposit Designation PTA-4097), and (ii) two heavy chains, each heavy chain comprising an expression product of either a plasmid designated pVgl:HuPRO140 HG2-VH (ATCC Deposit Designation PTA-4098) or a plasmic designated pVgl:HuPRO140 (mutB+D+I)-VH (ATCC Deposit Designation PTA-4099) or a fragment thereof which binds to CCR5 on the surface of a human cell.

    摘要翻译： 本发明涉及抗CCR5抗体，其包含（i）两条轻链，每条轻链包含命名为pVK：HuPRO14O-VK（ATCC保藏号PTA-4097）的质粒的表达产物，和（ii）两条重链 每个重链包含称为pVgl：HuPRO140HG2-VH（ATCC保藏号PTA-4098）或质粒命名为pVgl：HuPRO140（mutB + D + I）-VH（ATCC保藏号PTA-4099）的质粒的表达产物 ）或其与人细胞表面上的CCR5结合的片段。